Latest Capital Raising And Funding News

Arrow Minerals reports a breakthrough at its Niagara Bauxite Project with high-grade mineralisation over 14km² and advances metallurgical testwork at Simandou North, backed by a $7 million funding round.

Cauldron Energy’s December quarter report highlights a breakthrough uranium discovery at Manyingee South within the Yanrey Project, alongside a successful $4 million capital raise to fund ongoing exploration.

Tolu Minerals reports significant progress in recommencing production and expanding resources at its Tolukuma mine, underpinned by strategic hires and advanced geophysical surveys.

Kingston Resources delivered robust production and revenue growth at Mineral Hill in Q4 2024, while advancing a strategic review of its Misima Gold Project to unlock further value.

American West Metals has reported a substantial increase in its Storm Copper Project's mineral resource, alongside new high-grade copper discoveries and a successful A$7 million capital raise to fund further exploration and development.

Botala Energy has secured critical environmental approvals for its Serowe CBM Project and successfully raised A$1.87 million, positioning the company for commercial gas production in Southern Africa.

Carnaby Resources has significantly expanded its Greater Duchess Copper Gold Project through the acquisition of the high-grade Trekelano deposit, increasing its Mineral Resource Estimate by 27% and securing a key processing partnership with Glencore.

Native Mineral Resources Holdings Limited reported a net cash outflow for the December quarter, offset by a $4.1 million entitlement offer and additional funding commitments to sustain exploration activities.

One Click Group Limited reported a 42% increase in registered users and a 26% rise in revenue to $4.9 million in Q4 2024, while preparing to launch its new superannuation product in 2025.

Askari Metals reports significant exploration advances across its Australian gold and copper projects and secures a new uranium project in Tanzania, supported by fresh funding and leadership updates.

Control Bionics has delivered its strongest US sales quarter in years, nearing US$1 million in revenue, while broadening its market footprint with new commercial agreements and cost optimizations.

Percheron Therapeutics has terminated its phase IIb avicursen trial for Duchenne muscular dystrophy after failing to meet efficacy endpoints, while securing $14.85 million in fresh capital to explore new therapeutic opportunities.